Illumina (NASDAQ:ILMN) Cut to Hold at TD Cowen

TD Cowen cut shares of Illumina (NASDAQ:ILMN) from a buy rating to a hold rating in a research report report published on Friday, MarketBeat.com reports. TD Cowen currently has $140.00 price target on the life sciences company’s stock, down from their previous price target of $177.00.

ILMN has been the subject of several other reports. Barclays decreased their target price on Illumina from $145.00 to $130.00 and set an “equal weight” rating for the company in a research report on Monday, February 3rd. Canaccord Genuity Group boosted their target price on Illumina from $130.00 to $145.00 and gave the company a “hold” rating in a research report on Tuesday, November 5th. HSBC raised Illumina from a “hold” rating to a “buy” rating and set a $180.00 target price for the company in a research report on Thursday, October 17th. Citigroup downgraded Illumina from a “buy” rating to a “neutral” rating and cut their price target for the company from $190.00 to $165.00 in a research note on Wednesday, December 11th. Finally, Royal Bank of Canada lifted their price target on Illumina from $252.00 to $254.00 and gave the company an “outperform” rating in a research note on Tuesday, November 5th. Nine investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $161.40.

Illumina Trading Down 9.6 %

Shares of NASDAQ:ILMN opened at $111.06 on Friday. The business’s 50 day simple moving average is $136.70 and its 200 day simple moving average is $135.43. The company has a market capitalization of $17.61 billion, a P/E ratio of -14.46 and a beta of 1.10. Illumina has a 1 year low of $100.08 and a 1 year high of $156.66. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 12.59%. On average, research analysts anticipate that Illumina will post 4.42 EPS for the current fiscal year.

Institutional Trading of Illumina

A number of institutional investors have recently modified their holdings of ILMN. Cetera Investment Advisers raised its stake in Illumina by 25.8% in the second quarter. Cetera Investment Advisers now owns 18,384 shares of the life sciences company’s stock worth $1,919,000 after buying an additional 3,767 shares in the last quarter. Diversified Trust Co bought a new position in Illumina in the third quarter worth about $243,000. CWM LLC raised its stake in Illumina by 179.8% in the third quarter. CWM LLC now owns 16,207 shares of the life sciences company’s stock worth $2,114,000 after buying an additional 10,414 shares in the last quarter. Perpetual Ltd bought a new position in shares of Illumina during the third quarter valued at approximately $723,000. Finally, UMB Bank n.a. increased its stake in shares of Illumina by 23.7% during the third quarter. UMB Bank n.a. now owns 1,659 shares of the life sciences company’s stock valued at $216,000 after purchasing an additional 318 shares in the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.